https://jin-lab.org/ 2026-04-15T20:06:17+00:00 https://jin-lab.org/ https://jin-lab.org/lib/tpl/bootstrap3/images/favicon.ico text/html 2021-10-08T16:44:15+00:00 Anonymous (anonymous@undisclosed.example.com) https://jin-lab.org/doku.php?id=research:index&rev=1633704255&do=diff Research Developing CAR T cells for cancer therapy We are developing CAR T cells against new tumor antigens, novel CAR constructs for simultaneous therapy and imaging, and various ways to augment the potency of CAR T therapy against solid cancers. Our recent success include demonstration of somatostatin receptor-2 (SSTR2) for imaging T cell distribution and activity in vivo using PET/CT, and developing micromolar affinity CAR T cells to be selective to antigens over-expressed in tumor/tumor str… text/html 2014-05-29T19:48:47+00:00 Anonymous (anonymous@undisclosed.example.com) https://jin-lab.org/doku.php?id=research:no_flash--click_here&rev=1401385727&do=diff </box|Figure 8. In vivo imaging of systemic inflammation (Sepsis model) by ICAM-1 specific magnetic nanoparticles using Quantitative Susceptibility Mapping MRI technique. (A,C,E) Imaging by active I domain at 1, 8, 24h. (B,D,F) Imaging by inactive I domain at 1, 8, 24h.>| text/html 2014-05-29T19:48:47+00:00 Anonymous (anonymous@undisclosed.example.com) https://jin-lab.org/doku.php?id=research:no_flash_--click_here&rev=1401385727&do=diff </box|Figure 8. In vivo imaging of systemic inflammation (Sepsis model) by ICAM-1 specific magnetic nanoparticles using Quantitative Susceptibility Mapping MRI technique. (A,C,E) Imaging by active I domain at 1, 8, 24h. (B,D,F) Imaging by inactive I domain at 1, 8, 24h.>| text/html 2014-05-29T19:48:47+00:00 Anonymous (anonymous@undisclosed.example.com) https://jin-lab.org/doku.php?id=research:no_flash_player_--click_here&rev=1401385727&do=diff </box|Figure 8. In vivo imaging of systemic inflammation (Sepsis model) by ICAM-1 specific magnetic nanoparticles using Quantitative Susceptibility Mapping MRI technique. (A,C,E) Imaging by active I domain at 1, 8, 24h. (B,D,F) Imaging by inactive I domain at 1, 8, 24h.>| text/html 2014-05-29T19:48:47+00:00 Anonymous (anonymous@undisclosed.example.com) https://jin-lab.org/doku.php?id=research:specific_examples_of_project_i&rev=1401385727&do=diff A. Molecular engineering approach for developing molecules targeting disease markers <box 560px center grey></box|Figure 1. Selection of antibodies (A) and nucleic acid aptamers (B) against human proteins> We have developed a streamlined approach to discovering physiological ligands, antibodies, and aptamers against disease markers with high specificity and affinity (Fig 1). In addition to animal immunization for developing antibodies, we use in vitro platform consisting of functional display of… text/html 2014-05-29T19:48:47+00:00 Anonymous (anonymous@undisclosed.example.com) https://jin-lab.org/doku.php?id=research:specific_examples_of_project_ii&rev=1401385727&do=diff <box 380px left grey></box>Figure 7. In vitro (A) and in vivo (B&C) imaging of inflammation by specific targeting of human ICAM-1 and murine ICAM-1 by human LFA-1 I domain coated nanoparticles. Mice were injected with LPS at the right flank, indicated by dotted circles (B). (C) MRI (top: T2* image; bottom: susceptibility map) detection of the SPIO in the inflammation site of the lower right mouse after optical imaging in B. text/html 2014-05-29T19:48:47+00:00 Anonymous (anonymous@undisclosed.example.com) https://jin-lab.org/doku.php?id=research:specific_examples_of_project_iii&rev=1401385727&do=diff <box 380px left grey></box>Figure 9. Engineering adeno-associated virus for systemic deliver to the brain as a gene therapy vehicle. Despite high density vasculature network in the brain (A), the majority of the therapeutic and diagnostic agents do not reach the brain due to the blood-brain-barrier (B). By inserting in the AAV capsid a peptide targeting BBB-transport, we aim to achieve a systemic delivery of AAV to the brain.